Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Posterior Default Network Modulation in Alcohol Use Disorder

18 novembre 2026 aggiornato da: Martin Plawecki, Indiana University

This proposal will test whether repetitive transcranial magnetic stimulation (rTMS) modulation of the brain's posterior default mode network (pDMN) will alter alcohol craving, alcohol seeking and impulsivity in men and women who have an alcohol use disorder but are not seeking treatment.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Alcohol use disorder is a common medical condition affecting the lives of individuals worldwide. Many receive no treatment and relapse is high in those who do; there is a clear need for new and more effective treatments. This project will test whether the pDMN, a large-scale brain circuit most active at rest, is a potential target for therapeutic interventions.

rTMS non-invasively modulates regional cortical activity. Theta burst stimulation (TBS) is a variant of rTMS that utilizes two common patterns, continuous (cTBS) and intermittent (iTBS). This project will test the ability of cTBS and iTBS to change pDMN function, and affect alcohol seeking, alcohol craving, and impulsivity. A sham TBS treatment will be used for comparison.

Sixty participants with mild to moderate alcohol use disorder, who are not seeking treatment, will undergo baseline characterization for alcohol cue responsivity and delay discounting. They will then undergo three experimental days, in random order: (i) sham TBS, (ii) continuous (cTBS), or (iii) intermittent (iTBS). TBS will be delivered twice each experimental day. In the morning, TBS will be followed by a functional magnetic resonance imaging (fMRI) session that includes testing brain responses to alcohol and other taste cues, and delay discounting. Blood oxygenation level dependent (BOLD) contrasts will assess changes within relevant brain structures and across functional brain circuits. In the afternoon, TBS will be followed by an alcohol self-administration session during which small intravenous infusions of alcohol can be earned on a progressive ratio schedule. Number of infusions earned will be used to assess changes in alcohol motivation after TBS treatment.

Tipo di studio

Interventistico

Iscrizione (Stimato)

70

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Ann E Kosobud, PhD
  • Numero di telefono: 3172740087
  • Email: akosobud@iu.edu

Backup dei contatti dello studio

  • Nome: James M Hays
  • Numero di telefono: 3179486550
  • Email: haysjm@iu.edu

Luoghi di studio

    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46201
        • IU Health University Hospital
        • Investigatore principale:
          • Martin H Plawecki, MD, PhD
        • Contatto:
          • Study Recruiter
          • Numero di telefono: 3179486551
          • Email: erptest@iu.edu

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 21 anni a 55 anni (Adulto)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Men and women aged 21 - 55
  • Alcohol Use Disorder diagnostic criteria based on Interview, Screening, and Measures of at least moderate severity
  • ≥7 or 14 drinks/week average over the last month or ≥ 3 or 4 drinks/occasion for women and men respectively
  • Positive alcohol cue reactivity screening
  • Systematic Delay Discounting behavior
  • Right-handed

Exclusion Criteria:

  • Physical Exam, Vital Signs, Electrocardiogram, Laboratory Values, or screening assessment precluding safe participation or experimental procedures
  • Clinical Institute Withdrawal Assessment for Alcohol (CIWA) 177 ≥8 or reported significant risk symptoms
  • MRI contraindications
  • Pregnant or breast-feeding women; Women who do not attest to using accepted forms of birth control
  • Current or desire for AUD or substance use treatment
  • Medical conditions (e.g., seizure disorder) that may influence participant safety or study outcome)
  • Positive urine drug screen for amphetamines/ methamphetamines, barbiturates, benzodiazepines, cocaine, opiates, or phencyclidine and evidence of intoxication
  • Medications or dosage changes (past 30 days) that could influence participant safety or data (e.g., antidepressants, antipsychotics, benzodiazepines, etc.) or interact with alcohol
  • Current/history of neurological disease of cerebral origin, head injury with > 20 min loss of consciousness, medical treatment impacting MRI data, or serious psychiatric illness (bipolar disorder, psychosis).
  • Positive BrAC reading precluding visit completion
  • Actively suicidal or are at serious suicidal risk
  • Left-handed or ambidextrous
  • First degree family member with seizure disorder
  • Inability to understand English study instructions
  • Intoxication from any substance terminates an experimental day and will be considered for overall exclusion or study participation.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Sequence 1

On each of the three experimental study days, participants will undergo one of the following TBS treatment conditions: sham, continuous, or intermittent. Participants will receive all three treatment conditions in a randomly assigned order. To ensure participant blinding, the treatment order of this assigned sequence cannot be disclosed until the trial is concluded.

An IV alcohol self-administration session is conducted on each study day. Use of IV alcohol solutions is allowed under an FDA IND. It is a research tool and is not being tested for clinical use.

cTBS consists of a continuous train of 3-pulse bursts of neurostimulation.

iTBS consists of 2 second trains of 3-pulse bursts of neurostimulation, alternating with 8 seconds of rest.

Sham TBS duplicates the peripheral sensations of TBS without neurostimulation

Sterile alcohol is mixed with USP saline to a concentration of 6%

Sperimentale: Sequence 2

On each of the three experimental study days, participants will undergo one of the following TBS treatment conditions: sham, continuous, or intermittent. Participants will receive all three treatment conditions in a randomly assigned order. To ensure participant blinding, the treatment order of this assigned sequence cannot be disclosed until the trial is concluded.

An IV alcohol self-administration session is conducted on each study day. Use of IV alcohol solutions is allowed under an FDA IND. It is a research tool and is not being tested for clinical use.

cTBS consists of a continuous train of 3-pulse bursts of neurostimulation.

iTBS consists of 2 second trains of 3-pulse bursts of neurostimulation, alternating with 8 seconds of rest.

Sham TBS duplicates the peripheral sensations of TBS without neurostimulation

Sterile alcohol is mixed with USP saline to a concentration of 6%

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in pDMN BOLD responses to alcohol taste after iTBS, cTBS or sham treatment.
Lasso di tempo: 3 single day laboratory sessions scheduled 7-14 days apart

During the fMRI scan, two taste tests will be run, one alternating brief exposures to a preferred alcohol beverage and water, and a second alternating a sports drink with water. The primary comparison will be BOLD contrast [Flavor > Water] (where 'Flavor' is alcohol or sports drink) in the posterior default mode network (pDMN). Changes in response to alcohol-specific taste after iTBS, cTBS or sham treatments will be compared using linear or linear mixed models, controlling for age, biological sex, smoking, and subjective ratings (flavor liking and intensity, craving changes from baseline) and adjusting for multiple comparisons across regions.

3 single day laboratory sessions scheduled 7-14 days apart
Change in cue-induced craving after TBS.
Lasso di tempo: 3 single day laboratory sessions scheduled 7-14 days apart

In the Alcohol Cue Reactivity screen (ACR), a participant rates their current craving for alcohol before and after a 3 minute exposure to their preferred alcohol beverage in its typical glass (looking, smelling and handling the glass but not drinking). The ACR will be conducted before and after the morning TBS treatment. Change in alcohol craving after cTBS, iTBS or sham treatments will be compared using a linear or linear mixed model.

3 single day laboratory sessions scheduled 7-14 days apart
Change in the number of completed trials and alcohol infusions earned on a progressive ratio task after TBS.
Lasso di tempo: 3 single day laboratory sessions scheduled 7-14 days apart

During the alcohol infusion session, participants will be able to earn transient increases in infusion flow rate by completing a button pressing task. Number of trials required will increase after each earned infusion. The breakpoint is defined as the number of trials completed for the last infusion earned. Breakpoints after iTBS, cTBS and sham treatments will be compared using a linear or linear mixed model.

3 single day laboratory sessions scheduled 7-14 days apart
Change in impulsivity assessed using a delay discounting task after TBS.
Lasso di tempo: 3 single day laboratory sessions scheduled 7-14 days apart

Delay discounting estimates impulsivity by measuring preference for immediate versus delayed rewards. To optimize the task for scanning, monetary values and starting delays will be based on an individual's performance on the task during the interview. Changes in impulsivity after cTBS, iTBS and sham treatments will be assessed using a linear or linear mixed model.

3 single day laboratory sessions scheduled 7-14 days apart
Change in pDMN BOLD responses during a delay discounting task after TBS.
Lasso di tempo: 3 single day laboratory sessions scheduled 7-14 days apart

BOLD responses within the pDMN measured during the delay discounting task will be compared after cTBS, iTBS and sham treatments. Intervention (sham vs cTBS, and sham vs iTBS) and Group (sham-cTBS and sham-iTBS) contrasts will be assessed using linear or linear mixed models, controlling for age, biological sex, smoking, and subjective ratings (flavor liking and intensity, craving changes from baseline) and adjusting for multiple comparisons across regions.

3 single day laboratory sessions scheduled 7-14 days apart

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in pDMN functional connectivity during alcohol tasting after TBS treatment.
Lasso di tempo: 3 single day laboratory sessions scheduled 7-14 days apart

In separate scans, brief exposures to a preferred alcohol beverage or a sports drink will be alternated with water. Functional network connectivity will be assessed by calculating changes in the correlation between pairs of nodes within the pDMN.

3 single day laboratory sessions scheduled 7-14 days apart
Change in functional connectivity between the pDMN and salience network after TBS.
Lasso di tempo: 3 single day laboratory sessions scheduled 7-14 days apart

The effect of TBS treatments on functional network connectivity will be assessed by calculating changes in the correlation between pairs of nodes within the pDMN and the salience network. The difference in connectivity estimates after cTBS, iTBS and sham TBS will be assessed using linear mixed models.

3 single day laboratory sessions scheduled 7-14 days apart
Change in within-DMN functional connectivity during a delay discounting task after TBS.
Lasso di tempo: 3 single day laboratory sessions scheduled 7-14 days apart

During the delay discounting task, functional connectivity will be estimated from regional BOLD time series using Pearson correlations. Pairwise connectivity estimates will be computed for predefined region of interest pairs within the pDMN. The difference in connectivity estimates after cTBS, iTBS and sham TBS will be assessed using linear mixed models.

3 single day laboratory sessions scheduled 7-14 days apart
Change in functional connectivity between the pDMN and cognitive control areas after TBS.
Lasso di tempo: 3 single day laboratory sessions scheduled 7-14 days apart

Exploratory assessments will be conducted to detect other potentially important effects of TBS on connectivity between the pDMN and cognitive control areas. Contrasts between cTBS and iTBS will be compared during delay discounting and alcohol tasting.

3 single day laboratory sessions scheduled 7-14 days apart

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Martin H Plawecki, MD, PhD, Department of Psychiatry, Indiana University School of Medicine
  • Investigatore principale: David Kareken, PhD, Department of Neurology, Indiana University School of Medicine

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 gennaio 2027

Completamento primario (Stimato)

1 giugno 2031

Completamento dello studio (Stimato)

1 giugno 2031

Date di iscrizione allo studio

Primo inviato

12 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

18 novembre 2026

Primo Inserito (Effettivo)

20 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

18 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 24457
  • R01AA031671 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

We will contribute date to the National Data Archive as required by NIH. The final raw dataset will be available to other researchers when we have collected all subjects and completed our own planned analyses. Prior to completion of our own planned analyses, we would be willing to consider releasing the dataset upon request. We will work with our IRB to establish a strategy for de-identifying the data while retaining the ability to ensure the quality of the stored data.

Periodo di condivisione IPD

After all subjects have been collected and the primary outcomes accepted for publication. The dataset will be available indefinitely,

Criteri di accesso alla condivisione IPD

On request to the PIs

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .